Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
JAMA Netw Open. 2019 Jul 3;2(7):e198061. doi: 10.1001/jamanetworkopen.2019.8061.
Prescription opioid use is common among patients with moderate to severe knee osteoarthritis before undergoing total knee replacement (TKR). Preoperative opioid use may be associated with worse clinical and safety outcomes after TKR.
To determine the association of preoperative opioid use among patients 65 years and older with mortality and other complications at 30 days post-TKR.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study used claims data from January 1, 2010, to December 31, 2014, from a random sample of US Medicare enrollees 65 years and older who underwent TKR. Based on opioid dispensing in 360 days prior to TKR, patients were classified as continuous (≥1 opioid dispensing in each of the past 12 months) or intermittent (any dispensing of opioids in the past 12 months but not continuous use) opioid users or as opioid-naive patients (no opioids dispensed in the past 12 months). Data analyses were conducted from October 3, 2017, to November 8, 2018.
Primary outcomes included in-hospital mortality and 30-day post-TKR mortality, hospital readmission, and revision operation. Secondary safety outcomes at 30 days post-TKR included opioid overdose and vertebral and nonvertebral fracture. Multivariable Cox proportional hazards models estimated hazard ratios (HRs) and 95% CIs.
Of 316 593 patients (mean [SD] age, 73.9 [5.8] years; 214 677 [67.8%] women) who underwent TKR, 22 895 (7.2%) were continuous opioid users, 161 511 (51.0%) were intermittent opioid users, and 132 187 (41.7%) were opioid naive. In-hospital mortality occurred in 276 patients (0.09%). At 30 days post-TKR, 828 patients (0.26%) died, 16 786 patients (5.30%) had hospital readmission, and 921 patients (0.29%) had a revision operation. All primary and secondary outcomes occurred more frequently among continuous opioid users compared with opioid-naive patients. Compared with opioid-naive patients and after adjusting for demographic characteristics, combined comorbidity score, number of different prescription medications, and frailty, continuous opioid users had greater risk of revision operations (HR, 1.63; 95% CI, 1.15-2.32), vertebral fractures (HR, 2.37; 95% CI, 1.37-4.09), and opioid overdose (HR, 4.82; 95% CI, 1.36-17.07) at 30 days post-TKR. However, after adjusting covariates, there were no statistically significant differences in in-hospital (HR, 1.18; 95% CI, 0.73-1.90) or 30-day (HR, 1.05; 95% CI, 0.73-1.51) mortality between continuous opioid users and opioid-naive patients.
After adjusting for baseline risk profiles, including comorbidities and frailty, continuous opioid users had a higher risk of revision operations, vertebral fractures, and opioid overdose at 30 days post-TKR but not of in-hospital or 30-day mortality, compared with opioid-naive patients. These results highlight the need for better understanding of patient characteristics associated with chronic opioid use to optimize preoperative assessment of overall risk after TKR.
重要性:接受全膝关节置换术(TKR)的中重度膝骨关节炎患者术前常使用处方类阿片类药物。TKR 术后,术前使用阿片类药物可能与更差的临床和安全结局相关。
目的:确定 65 岁及以上患者术前使用阿片类药物与 TKR 术后 30 天内死亡和其他并发症的关系。
设计、设置和参与者:这项队列研究使用了 2010 年 1 月 1 日至 2014 年 12 月 31 日来自美国 Medicare 登记患者的随机样本的索赔数据,这些患者年龄均在 65 岁及以上,且接受了 TKR。根据 TKR 前 360 天的阿片类药物配药情况,将患者分为连续(过去 12 个月中每个月都有 1 次以上的阿片类药物配药)或间歇性(过去 12 个月中有任何阿片类药物配药但不是连续使用)阿片类药物使用者或阿片类药物未使用者(过去 12 个月内没有配给阿片类药物)。数据分析于 2017 年 10 月 3 日至 2018 年 11 月 8 日进行。
主要结局和测量:主要结局包括院内死亡率和 TKR 术后 30 天死亡率、医院再入院和翻修手术。TKR 术后 30 天的次要安全性结局包括阿片类药物过量、椎体和非椎体骨折。多变量 Cox 比例风险模型估计了风险比(HR)和 95%置信区间(CI)。
结果:在 316593 名接受 TKR 的患者中(平均[SD]年龄为 73.9[5.8]岁;214677[67.8%]为女性),22895 名(7.2%)为连续阿片类药物使用者,161511 名(51.0%)为间歇性阿片类药物使用者,132187 名(41.7%)为阿片类药物未使用者。院内死亡率为 276 例(0.09%)。TKR 术后 30 天,828 例(0.26%)死亡,16786 例(5.30%)发生医院再入院,921 例(0.29%)进行了翻修手术。所有主要和次要结局在连续阿片类药物使用者中比阿片类药物未使用者更常见。与阿片类药物未使用者相比,并且在调整了人口统计学特征、合并共病评分、不同处方药物数量和脆弱性后,连续阿片类药物使用者在 TKR 术后 30 天发生翻修手术(HR,1.63;95%CI,1.15-2.32)、椎体骨折(HR,2.37;95%CI,1.37-4.09)和阿片类药物过量(HR,4.82;95%CI,1.36-17.07)的风险更高。然而,在调整了协变量后,连续阿片类药物使用者与阿片类药物未使用者之间在院内(HR,1.18;95%CI,0.73-1.90)或 30 天(HR,1.05;95%CI,0.73-1.51)死亡率方面没有统计学差异。
结论和相关性:在调整了基线风险特征,包括合并症和脆弱性后,与阿片类药物未使用者相比,连续阿片类药物使用者在 TKR 术后 30 天发生翻修手术、椎体骨折和阿片类药物过量的风险更高,但在院内或 30 天死亡率方面没有更高的风险。这些结果强调了需要更好地了解与慢性阿片类药物使用相关的患者特征,以优化 TKR 后整体风险的术前评估。